title: The effect of propranolol on cerebrovascular reactivity to visual stimulation in migraine.
abstract: BACKGROUND
  Propranolol is effective for migraine prophylaxis. However, its exact mechanism is not known. We postulated that the protective effect is due to the lowering of cerebrovascular reactivity (CVR). To verify this, we applied photic stimuli to migraineurs and analyzed the results.
  
  
  METHODS
  We checked the mean flow velocity (MFV) of the posterior cerebral artery by transcranial Doppler in 22 migraineurs during a headache-free period and in 14 normal controls. During the photic stimulation, MFV was remeasured and the CVR was estimated in both groups. Migraineurs received prophylactic propranolol for 2 months, and they were then reevaluated for the above-mentioned parameters and assessed for a headache index (HI).
  
  
  RESULTS
  There were no baseline differences in MFV between migraineurs and controls before treatment. Both groups showed a similar degree of increase in MFV with the photic stimulation, thus CVR was not significantly different between them. After the treatment period, CVR decreased significantly in migraineurs compared to baseline (p<0.01), although MFV remained unchanged. The prophylactic effect of propranolol treatment on symptomatic migraine was demonstrated on the HI, which significantly improved (p<0.05).
  
  
  CONCLUSIONS
  Considering that CVR was decreased but the baseline MFV was not changed in the posterior cerebral artery prior to the visual stimulation in migraineurs after propranolol treatment, we assume that the protective effect of propranolol was not due to the direct effect on the cerebral vessels but due to the modulation of the CVR to sensory stimulation through its action on central centers associated with autonomic vascular tone.
authors.affiliation: Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Gangnam-gu, Seoul, 135-710, Republic of Korea.
authors.forename: Ju-Hong
authors.initials: JH
authors.lastname: Min
authors.forename: Hyung-Min
authors.initials: HM
authors.lastname: Kwon
authors.forename: Hyunwoo
authors.initials: H
authors.lastname: Nam
mesh_terms: D000328:Adult; D001341:Autonomic Nervous System / Q000187:drug effects / Q000502:physiology; D002560:Cerebrovascular Circulation / Q000187:drug effects* / Q000502:physiology; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000503:physiopathology* / Q000517:prevention & control; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D010775:Photic Stimulation / Q000009:adverse effects; D020769:Posterior Cerebral Artery / Q000187:drug effects / Q000294:innervation / Q000503:physiopathology; D011433:Propranolol / Q000627:therapeutic use*; D016037:Single-Blind Method; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D014666:Vasomotor System / Q000187:drug effects / Q000502:physiology
chemical_list: D014665:Vasodilator Agents; D011433:Propranolol